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ABSTRACT 
Dyslipidemia is a biochemical derangement found in number of disorders like Diabetes mellitus, 
Hypertension, Hypothyroidism etc. Dyslipidemia is an important risk factor for atherosclerosis, coronary 
artery disease and cerebrovascular disease. Epidemiological studies predict that for each 1% reduction in 
level of LDL-C there is 1% to 1.5% reduction in the risk of major cardiovascular events. Fewer than one half 
of patients in the United States discharged from the hospital with proven coronary disease receive treatment 
for Dyslipidemia given the proof that treating Dyslipidemia brings major benefits. Thus  global views 
emphasize the need for early; effective interventions against the Atherogenic Dyslipidemia associated with 
Diabetic and Non-Diabetic cases and with metabolic syndrome to reduce the risk of premature 
cardiovascular diseases. In Ayurveda, it can be better correlated with Medodushti which is a functional 
condition and just a precursor stage of Medoroga and can be easily reversible by effective regimen. A single 
blind Study was carried out in OPD and IPD patients of Kayachikitsa department of Rishikul Campus, 
Haridwar for 90 days. Total 20 patients were registered for the trial and treated with TGL compound (Self-
formulated drug). All the concerned approvals were obtained and data was analyzed under statistical 
parameters. A significantly reduction of cholesterol level, Triglycerides, VLDL, CHO/HDL Ratio and highly 
significant reduction of LDL and LDL/HDL Ratio was found. This research also proved the major role of Agni 
and Ama in pathogenesis of Dyslipidemia, and all the drugs having Dipana, Pachana, Ama nashaka, Kapha-
Medohara, Rasayana and Srotoshodhaks quality will be highly effective.  
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INTRODUCTION
 The two main lipids in blood are Cholesterol and 
Triglycerides. They are carried in lipoproteins, globular 
particles that also contain proteins known as apoproteins. 
Lipoproteins are transport vehicle of lipids which 
transport lipids between peripheral tissues and liver. 
Cholesterol is an essential element of all animal cell 
membranes and forms the backbone of steroid hormones 
and bile acids. Triglycerides are important in transferring 
energy from food into cells.1-2 
 In Dyslipidemia there is increased lipids in the 
blood resulting either from an increased rate of synthesis 
or from a decreased lipoprotein breakdown rate3. The 
raised level of cholesterol leads to deposition of lipids 
(mainly in form of esterified cholesterol) in the wall of 
arteries and causes Atherosclerosis. Atherosclerosis affects 
various regions of the circulation preferentially and yield 
distinct clinical manifestations depending on the particular 
circulatory bed affected4. In Allopathic system of medicine, 
we have a wide range of drugs like statins, resins, fibric 
acid derivatives, nicotinic acid etc. which are quiet 
effective in normalizing the lipid levels but they also have 
side effects like headache, nausea, bowel upset, rashes, 
sleep disturbances, Myalgia, increase level of Serum 
Transaminase which can further leads to Liver damage 
etc5. A recent research on Atorvastatin has proved that a 
high dose of Atorvastatin for longer duration make the 
patients prone for development of Diabetes6. 
 Dyslipidemia cannot be directly correlated with 
any disease conditions describes in Ayurvedic classics but 
the concept of Abaddha Meda expounded by Acharya 
Chakrapan7 have similarity with the condition of 
Dyslipidemia describe in modern science. The symptoms 
of Dyslipidemia described in modern text shows 
resemblance with Aam, and with many of Rasa dushti, 
Rakta dushti, and Medodushti janya symptoms. Many 
attempts were made by various scholars of Ayurveda to 
clinically correlate it to Rasagata sneha vriddhi (increased 
lipids in plasma), Raktagata sneha vriddhi (increased lipids 
in blood), Rasaraktagata sneha vriddhi (increased lipids in 
plasma and blood)8. Being a disorder of Meda dhatu, we 
have correlated it with “Medo dushti” (Aam dushit Meda 
dhatu).  
AIMS AND OBJECTIVES  
The aims and objectives of the study were: 
 To study the aetiopathogenesis of Dyslipidemia and 
work out the Ayurvedic correlations. 
 To evaluate the efficacy of TGL compound in the 
management of Dyslipidemia by using various 
scientific parameters. 
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 To provide a reliable, cost effective Ayurvedic 
treatment for Dyslipidemia. 
MATERIAL & METHODS 
 The study was single blind Study and carried out 
in OPD and IPD patients of Kayachikitsa department of 
Rishikul Campus, Haridwar for 90 days. Total 20 patients 
were registered for the trial and treated with TGL 
compound (Self-formulated drug). All the concerned 
approvals were obtained. 
 According to NCEP (National cholesterol 
education program) adult treatment panel 3, following 
range value was taken for diagnosis of dyslipidemia.9  
a) S. Cholesterol : { >200mg/dl} 
b) S.Triglycerides: {>150mg/dl} 
c) S.LDL :{>130 mg/dl} 
d) S.VLDL: {>40 mg/dl} 
e) S. HDL: {<40 mg/dl} 
f) Cho/HDL. Ratio : (>4.97) 
g) LDL / HDL Cho. Ratio : (>3.55) 
Inclusion Criteria 
a) Diagnosed & confirmed cases of Dyslipidemia on the 
basis of investigation. 
b) Patient between the age group of 20-60 years of either 
sex who fulfill the criteria of Objective and Subjective 
parameters 
c) Newly diagnosed case of NIDDM with optimal control 
Diabetes was also considered under study. 
Exclusion Criteria 
a)-Patients with age below 20 years & above 60 years 
b)-Patients suffering from type 1 Diabetes mellitus and 
uncontrolled Diabetes mellitus or uncontrolled 
Hypertension. 
C)-Drug induced or uncontrolled Dyslipidemia. 
d)-Patient having systemic illness like Tuberculosis, 
Carcinoma and Endocrine disorders or major illness like 
Renal or Liver disorder. 
e)-Patient having the past history of Myocardial infarction 
& Unstable Angina. 
f)-Patient having clinical features of CCF. 
Ingredients of TGL COMPOUND 
The formulation composition of TGL Compound along with 
the proportion and part used of individual components is 
depicted at table no.1 
Method of preparation of TGL COMPOUND 
 The content of Trikatu churna i.e. Pippali, Maricha, 
and Shunti were taken in powder form and mixed with 
Guggul resin purified by Triphala decoction. A fresh paste 
of Lahsuna was taken. After mixing above mixtures, tablets 
weighted 500mg each were prepared with the help of 
tablet forming machine. 
Drug Trial Schedule 
Drug: TGL compound 
Form: Tablet 
Dose: 2 Tablets (Each 500 mg.) 
Twice in a day 
Mode of administration: Oral 
Time of administration: before meal 
Anupana : Luke warm water 
Duration : 90 days 
RESULT & DISCUSSION  
 Dyslipidemia is a disorder of Agnimandya and 
Sama Rasa formation which leads to obstruction in the 
channels hence to manage this condition the selected drug 
should be of Dipana, Pachana, Kaphanashaka, Medhoghna 
and Srotoshodhaka properties. The researches on 
Dyslipidemia suggest that Laghu, Ruksha, and Kashaya 
Rasa dominant formulation is more effective against 
Cholesterol and LDL, while Laghu, Ushna, Katu Rasa 
dominant formulation is effective in condition of 
hypertriglycerdemia15-16. TGL compound fulfills all 
requirements which we needed in the management of 
Medodushti. The contents of TGL compound are Trikatu, 
Guggul, and Lahsun (Rasona). The objective assessment of 
results was based on laboratory investigations and data 
was analysed by using statistical “paired t test”. Results 
was highly significant (p <0.001) in lowering Sr. LDL and 
LDL/HDL Ratio while it was significant in lowering Sr. 
Cholesterol (p< 0.01), Sr. VLDL (p<0.01), Sr. Triglycerides 
(p<0.05) and cholesterol/HDL ratio (P<0.05). A significant 
increased in level of HDL was also noted which is known as 
“good cholesterol”, helps in removal of LDL Cholesterol 
from arterial walls and preventing the process of 
atherosclerosis. 
CONCLUSION 
 The contents of TGL compound are Pippiali, 
Maricha, Shunthi, Guggulu and Lahsuna contain Ushna, 
Tikshna Guna, Katu Rasa and Deepana, Pachana property 
and thus increase Agnibala and reduces Kapha, Aam and 
Kleda. Trikatu and Guggulu possesses Lekhana property 
and thus had decreased Meda and Sthaulya. Lasuna 
possesses Deepana, Pachana, Anulomana and Sroto 
Vibandhahara property and thus removes the Avarana of 
Vata caused by Kapha and Meda. Guggul content of TGL 
compound is more useful in Pre-Diabetic and Dyslipidemic 
patients while Lasuna is more useful in the patients of 
Dyslipidemia with Hypertension. Lasuna has additional 
advantage of improving digestion process. Hence it can be 
concluded by present clinical trial that due to its Guggul 
content TGL Compound can be used in Kapha, Meda and 
Kleda Bahula Sampraptijanya Vyadhi. These drugs basically 
are Katu and Tikta Rasa pradhan, Ushna Veerya and Laghu 
Ruksha Guna, this formulation helps in eliminating vitiated 
Kapha. It also corrects the vitiated both Medas and Kapha 
being the main entity of the Samprapti, thus by breaking 
the Samprapti (correcting the vitiation of Medas and 
Kapha) treats the disease. As the drug is Ushna it also 
increased improving the Dhatvagni, (as Ayurveda believes 
that the disease is Amajanya). In this way the properties of 
all five contains of drug help in Samprapti Vighatana of the 
disease. 
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Table 1: Properties TGL Compound 
Name Pippali10 Marich11 Sunthi12 Guggulu13 Lashun14 
Botonical 
name 
Piper longum Piper nigrum Zingiber 
officinalis 
Commiphora mukul Allium sativum 
Family Piperaceae Piperaceae Zingiberaceae Burseraceae Lilliaceae 
Ras  Katu Katu  Katu Tikta, Katu  Pancha ras except 
Amla 
Guna  Laghu, Snigdha, 
Tikshna 
Tikshna, laghu  Laghu, Snigdha (Puran guggulu)-Tikshna, 
Laghu, Ruksha, Vishad, 
Sukshma, Sar, Sugandhi 
Snigdha, Tikshna, 
Picchila, Guru, Sar 
Virya  Anushnshita  Ushna Ushna Ushna Ushna 
Vipak  Madhura  Katu  Madhura Katu  Katu  
Doshakarma Kaphavaatsham
aka 
Kaphavaatshamaka  Kaphavaatshamaka Vaatshamaka, 
Medoavartavaatshamaka 
Kapha 
vaatshamaka  
Active 
principle 
 Piperine (4-
5%), piplartine 
piperin (5-10%), 
piperidine (5%), 
piperittine. 
Zingiberene 
(35.6%), Zingiberol 
 Raal (35-61%), resin 
(29.3%) 
allyl- propyl 
sulphide 6%, 
diallyl- disulphide 
Prabhav    Tridoshahar  
Proportion  1/3 1/3 1/3 1 1 
Form Powder Powder Powder Resin Paste 
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Table 2: Statistical analysis of Overall parameters 
 Mean score ±S.D % relief ‘t’ Value P Value 
B.T A.T 
1. S.Cholesterol 225.45±56.3 187±47.4 17.03% 3.6216 <0.01 
S 
2. S.Triglycerides 226.6±83.89 178.7±80.7 21.1% 2.6527 <0.05 
S 
3. S.HDL 39.85±6.72 41.35±8.26 3.7% (-) 0.812 >0.05 
NS 
4. S.LDL 152.25±49.3 106.75±35. 29.9% 5.7496 <0.001 
HS 
5. S.VLDL 45.25±27.5 31.2±18.91 31.04% 3.3227 <0.01 
S 
6. Cholesterol/HDL Ratio 5.87±1.98 5.01±1.36 14.% 2.80 <0.05 
S 
7. LDL/HDL Ratio 3.97±2.10 2.75±1.03 30.7% 4.63 <0.001 
HS 
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